makaule / iStockphoto.com
Eli Lilly experienced a setback yesterday at the US Court of Appeals for the Federal Circuit when it affirmed that a patent owned by the company is invalid.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eli Lilly, Actavis, Lupin, Watson, Amneal, US Court of Appeals for the Federal Circuit, patent, patent infringement, ANDA, generics